Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the target of unusually large options trading activity on Wednesday. Investors acquired 1,002 put options on the company. This represents an increase of approximately 1,791% compared to the typical daily volume of 53 put options.

Maravai LifeSciences Stock Up 1.8%

MRVI opened at $2.27 on Thursday. The company has a current ratio of 5.96, a quick ratio of 5.17 and a debt-to-equity ratio of 0.60. Maravai LifeSciences has a 1-year low of $1.67 and a 1-year high of $10.03. The company has a market capitalization of $578.08 million, a PE ratio of -1.99 and a beta of 0.25. The firm's 50 day simple moving average is $2.12 and its two-hundred day simple moving average is $3.34.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $46.85 million for the quarter, compared to the consensus estimate of $44.01 million. Maravai LifeSciences had a negative net margin of 67.14% and a negative return on equity of 12.91%. The business's revenue for the quarter was down 26.9% on a year-over-year basis. As a group, equities analysts forecast that Maravai LifeSciences will post -0.24 EPS for the current year.

Institutional Trading of Maravai LifeSciences

Several institutional investors and hedge funds have recently modified their holdings of the company. 12 West Capital Management LP raised its position in shares of Maravai LifeSciences by 8.0% during the 1st quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company's stock valued at $27,672,000 after purchasing an additional 930,000 shares during the period. Alyeska Investment Group L.P. raised its position in shares of Maravai LifeSciences by 145.8% during the 4th quarter. Alyeska Investment Group L.P. now owns 5,329,420 shares of the company's stock valued at $29,045,000 after purchasing an additional 3,161,072 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in Maravai LifeSciences by 29.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,664,210 shares of the company's stock valued at $25,420,000 after acquiring an additional 1,062,485 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Maravai LifeSciences by 4.9% in the 4th quarter. JPMorgan Chase & Co. now owns 4,250,656 shares of the company's stock valued at $23,166,000 after acquiring an additional 200,411 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in Maravai LifeSciences by 1.8% in the 4th quarter. Ameriprise Financial Inc. now owns 3,611,625 shares of the company's stock valued at $19,683,000 after acquiring an additional 62,123 shares during the last quarter. 50.25% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on MRVI shares. Baird R W cut shares of Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 26th. Morgan Stanley cut their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a report on Tuesday, March 25th. Craig Hallum cut their price objective on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. UBS Group cut their price objective on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a report on Friday, March 21st. Finally, Stifel Nicolaus set a $5.00 price objective on shares of Maravai LifeSciences in a report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Maravai LifeSciences has an average rating of "Hold" and an average price target of $6.64.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.